Prevalence of and risk factors for HCV among incarcerated people at Great Tehran Prison: a cross-sectional study.

PURPOSE Hepatitis C is one of the major health issues in both developed and developing countries. Hepatitis C virus (HCV) infection is more common in prisoners than in the general population. The purpose of this study was to determine the prevalence of HCV and its associated risk factors in Iranian male prisoners in Tehran. DESIGN/METHODOLOGY/APPROACH In this cross-sectional study, the authors investigated the frequency and risk factors of hepatitis C infection among male prisoners in the Great Tehran Prison. Information on risk factors including the length of imprisonment, previous history of imprisonment, history of drug injection, history of tattooing, history of piercing, history of high-risk sex and family history of hepatitis C were extracted from patients' records. To evaluate HCV status, blood samples were collected and tested. FINDINGS In this study, 179 participants were included. Nine participants (5.0%, 95% CI, 2.3-9.3) were positive for hepatitis C. HCV infection was not significantly associated with age, marital status, education, previous history of imprisonment, length of imprisonment, piercing and high-risk sex; however, there was a significant association between a history of tattooing and a history of injecting drug use and Hepatitis C. ORIGINALITY/VALUE The prevalence of hepatitis C among male prisoners in Great Tehran Prison was 5% in this study, similar to recent studies on prisoners in Tehran. A history of drug injections as well as tattooing were the most important risk factors for hepatitis C in male prisoners.

[1]  M. Alavi,et al.  Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta‐analysis , 2021, Journal of viral hepatitis.

[2]  D. Studdert,et al.  Hepatitis C Treatment in Prisons - Incarcerated People's Uncertain Right to Direct-Acting Antiviral Therapy. , 2020, The New England journal of medicine.

[3]  Mohammad Gholami-Fesharaki,et al.  Prevalence of Hepatitis C Virus in Iranian Prisoners: An Updated Systematic Review and Multilevel Meta-Analysis Study , 2020, Hepatitis Monthly.

[4]  G. Moradi,et al.  Prevalence and risk factors for HBV and HCV among incarcerated people who inject drugs in Iran: a cross sectional study , 2020 .

[5]  H. Ekhtiari,et al.  The Evolution of Addiction Treatment and Harm Reduction Programs in Iran: A Chaotic Response or a Synergistic Diversity? , 2019, Addiction.

[6]  S. Ghafari,et al.  Prevalence of Hepatitis B and C among Drug-Abusing Male Prisoners in Birjand, South Khorasan, Iran. , 2019, Archives of Iranian medicine.

[7]  G. Moradi,et al.  Prevalence and Risk Factors for Hepatitis B and Hepatitis C Exposure in Iranian Prisoners: A National Study in 2016 , 2019, Hepatitis Monthly.

[8]  G. Moradi,et al.  Prevalence and risk factors for HBV and HCV in prisoners in Iran: a national bio‐behavioural surveillance survey in 2015 , 2018, Tropical medicine & international health : TM & IH.

[9]  M. Behzadifar,et al.  Prevalence of hepatitis C virus infection among prisoners in Iran: a systematic review and meta-analysis , 2018, Harm Reduction Journal.

[10]  L. Tavoschi,et al.  Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups , 2018, BMC Infectious Diseases.

[11]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[12]  Reza Assadi,et al.  The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.

[13]  M. Mckee,et al.  Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees , 2016, The Lancet.

[14]  J. Lazarus,et al.  Urgent action to fight hepatitis C in people who inject drugs in Europe , 2016, Hepatology, Medicine and Policy.

[15]  S. Alavian,et al.  Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden , 2016, Hepatitis monthly.

[16]  A. Mirzazadeh,et al.  HIV, HBV and HCV Coinfection Prevalence in Iran - A Systematic Review and Meta-Analysis , 2016, PloS one.

[17]  M. Mohraz,et al.  Tuberculosis, hepatitis C and hepatitis B co-infections in patients with HIV in the Great Tehran Prison, Iran , 2016 .

[18]  M. Mahjoob,et al.  Prevalence of Hepatitis B and C in Male Prisoners in Iranian Prisons , 2015 .

[19]  A. Rahimi-Movaghar,et al.  High hepatitis C virus prevalence among drug users in Iran: systematic review and meta-analysis of epidemiological evidence (2001-2012). , 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[20]  J. Ward,et al.  Launch of a Nationwide Hepatitis C Elimination Program — Georgia, April 2015 , 2015, MMWR. Morbidity and mortality weekly report.

[21]  M. Abdel-hamid,et al.  Hepatitis C virus acquisition among Egyptians: analysis of a 10‐year surveillance of acute hepatitis C , 2015, Tropical medicine & international health : TM & IH.

[22]  I. Marijanović,et al.  Risk behaviour of prison inmates in relation to HIV/STI. , 2014, Psychiatria Danubina.

[23]  A. Mirzazadeh,et al.  HIV prevalence and related risk behaviours among prisoners in Iran: results of the national biobehavioural survey, 2009 , 2013, Sexually Transmitted Infections.

[24]  Christiane,et al.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. , 2013, JAMA.

[25]  N. Pai,et al.  Incidence of acute hepatitis C virus infection among men who have sex with men with and without HIV infection: a systematic review , 2012, Sexually Transmitted Infections.

[26]  Peter Vickerman,et al.  Mathematical modelling of hepatitis C treatment for injecting drug users. , 2011, Journal of theoretical biology.

[27]  H. Poustchi,et al.  Incarceration is a major risk factor for blood-borne infection among intravenous drug users , 2011, Hepatitis monthly.

[28]  G. Friedland.  Infectious Disease Comorbidities Adversely Affecting Substance Users With HIV: Hepatitis C and Tuberculosis , 2010, Journal of acquired immune deficiency syndromes.

[29]  W. Mcfarland,et al.  Prevalence and Correlates of Hepatitis C Infection among Male Injection Drug Users in Detention, Tehran, Iran , 2009, Journal of Urban Health.

[30]  O. Oguntibeju,et al.  Prevalence of risk factors for transmission of HIV and blood-borne viruses in a prison population , 2009 .

[31]  R. Malekzadeh,et al.  Hepatitis C seroprevalence among intravenous drug users in Tehran , 2008 .

[32]  Theodore Y Sy,et al.  Epidemiology of Hepatitis C Virus (HCV) Infection , 2006, International journal of medical sciences.

[33]  R. Malekzadeh,et al.  HCV IN INTRAVENOUS DRUG USERS , 2005 .

[34]  D. Dufour,et al.  Lot-to-lot variation in anti-hepatitis C signal-to-cutoff ratio. , 2004, Clinical chemistry.

[35]  L. Joseph,et al.  Tattooing and risk for transfusion-transmitted diseases: The role of the type, number and design of the tattoos, and the conditions in which they were performed , 2002, Epidemiology and Infection.

[36]  A. Nowroozi,et al.  ANTI-HCV ANTIBODY AMONG IRANIAN IV DRUGUSERS: IS IT A SERIOUS PROBLEM? , 2001 .

[37]  L. Seeff,et al.  Hepatitis C: a brief clinical overview. , 2001, ILAR journal.

[38]  J. McCormick,et al.  Unsafe injections and the transmission of hepatitis B and C in a periurban community in Pakistan. , 2000, Bulletin of the World Health Organization.

[39]  J. Hoofnagle,et al.  Hepatitis C in asymptomatic blood donors , 1997, Hepatology.